ArticleJournal of neuro-oncology2016

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.

D Jay McCracken et al.PubMed ↗Publisher ↗

No numbers read from the abstract.